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The tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) consists of a 
desmoplastic fibrous stroma along with tumor cells, fibroblast and immune cells, resulting in a 
dense, hypovascularized environment resistant to all conventional treatments. While treatment of 
other cancers has improved markedly during the last years, the long-term survival of PDAC 
patients has not. Recent research has emphasized the role of tumor stroma, and its importance in 
impeding the efficacy of treatments and accelerate tumor progression. Therefore, Innovative pre-
clinical models, which take the tumor/stroma interaction into account, are urgently needed. 
 
In this study, we expanded a novel pre-clinical model system for PDAC using decellularized 
porcine small intestine (SISser) and pancreas (PanMA) as biological scaffolds, with the potential 
to reflect the complex three-dimensional extracellular matrix composition more accurately. Real-
time visualization by confocal microscopy was utilized to optimize experimental efficiency for 
different PDAC cell lines. With this system, morphology and growth kinetics of PDAC cells were 
analyzed in monoculture and in coculture with pancreatic stellate cells (PSCs), to evaluate their 
interactions. 
 
Different PDAC cell lines retain their unique growth pattern and kinetics, both in monoculture and 
coculture within the model system. We monitored interactions between PDAC cell lines and PSCs 
showing statistical significance in PSC growth kinetics while PDAC growth kinetics remained 
unchanged. We show that cellular behavior is affected by organ specific cues of the scaffold and 
highlight the significance of the matrix for tumor development. We examined the effect of dynamic 
culture conditions on PDAC cells with SISser scaffolds. And finally, we examined the applicability 
of our model system for PDAC therapy by testing efficacy of gemcitabine. 
Our 3D model system show promise as a pre-clinical niche, by maintaining complex extracellular 




1.1 Pancreatic ductal adenocarcinoma   
Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all pancreatic     
neoplasms (1), and is one of the leading causes of cancer deaths in the industrialized world with 
56700 new cases and 45750 deaths in the US alone, in 2019. Significant advances in PDAC have 
been made the last decades, however, the 5 year survival of PDAC is ~9%, with slow progression 
for improving long-term survival  rate (2). The median diagnosis age for a PDAC patient is 70, 
often with late-stage detection. Due to very vague symptoms and a lack of a valid biomarker, 
PDAC is often detected after metastasis. The majority of PDAC cases are irregular with no known 
genetic predisposition (3,4). 
 
PDAC emerges from the epithelial cells of the pancreatic ducts and follows a stepwise 
development similar to other carcinomas, most notably to colon carcinoma (5). Several distinct 
types of precursor lesions have been described, most common are microscopic pancreatic 
intraepithelial neoplasia (PanIN), which are divided into PanIN-1 and PanIN-2 (low grade) and 
PanIN-3 (high grade). Low grade lesions are associated with normal adult pancreas or patients 
with chronic pancreatitis with a low risk of PDAC development, while high grade lesions are for 
the most part, solely found in patients with invasive PDAC (6). 
Other types of precursor lesions include macroscopic cysts; most notably the intraductal papillary 
mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN) which have the possibility to 
become invasive PDAC (7). 
 
It is estimated that around 30% of all cancers have an oncogenic mutation in one of the Ras genes; 
H-Ras, N-Ras and K-Ras. Mutations in the Ras gene family usually results in a gain-of-fuction 
and constitutive activation of the Ras-gene.  PDAC rarely acquires mutations of H-Ras and N-Ras, 
but almost exclusively on the K-Ras locus with mutation rates of the gene reported to be upwards 
of 95% of all PDACs (8). Loss of function of the tumor suppressor P16/CDKN2A also shows very 




The poor long-term survival is due to a combination of late-stage detection, invasive and metastatic 
phenotypes of PDAC and that they are resistant to all conventional treatments. Treatments for 
PDAC include surgical removal, chemotherapy and radiation. Surgical removal of the tumor is 
still the best standard care for small tumors that have not metastasized. This increases the 5-year 
survival rate to 20%. Unfortunately, only 20% of PDAC cancers are resectable. Surgery is not 
possible when the tumor invades the superior mesenteric artery or coeliac axis (10). Radiotherapy 
has been used in an adjuvant setting, most commonly in post-surgery. However, the results have 
been conflicting and controversial (11). Immunotherapies targeting checkpoint inhibitors have yet 
to prove their efficacy, theorized to be because of a low immunogenic microenvironment (12). 
Unfortunately in PDAC, only chemotherapies have demonstrated efficacy. 
 
In PDAC, chemotherapies are chosen based on the patient’s fitness and different health factors.  
Gemcitabine (GEM) is a chemotherapeutic agent used to treat several cancers, including PDAC.  
Older patients or patients in general poor health condition are treated with GEM and nab 
(nanoparticle albumin-bound) paclitaxel, which show a good response rate and a significantly 
improved overall survival of 6.8 months (13,14). For young and healthy patients, FOLFIRINOX, 
consisting of Leucovorin plus short-term fluorouracil infusion plus oxaliplatin and irinotecan is 
the preferred treatment. Studies have shown that patients given FOLFIRINOX have a median 
survival time of 11.1 months. However, FOLFIRINOX has more severe side effects, including 
febrile neutropenia, thrombocytopenia, neuropathy and diarrhea (15). Since chemotherapies target 
proliferating cells, the limited treatment efficacy is hypothesized to be cause by the development 
of chemoresistance (16) and a dense hypo-vascularized tumor stroma that impairs drug delivery, 
making the drugs obsolete(17). Therefore, the development of novel therapies is crucial for 
improving the long-term survival rate of PDAC patients.   
 
1.2 Tumor stroma  
One main characteristic of PDAC tumors that was clearly underestimated in previous treatments 
attempts was the desmoplastic stroma of PDAC. Defined by fibrous connective tissue, it can 
comprise up to 90% of the tumor volume. The remaining components consist of tumor cells, cancer 
associated fibroblast (CAFs),  immune cells and other stromal components (18). The stroma is 
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defined by both cellular components such as fibroblast and immune cells, and non-cellular 
components including extracellular matrix (ECM) as collagen, laminins and hyaluronan. The 
different components provide a scaffolding system to support the tumor cells and provides the 
ability for communication between different cells. The cells can communicate with each other by 
direct contact or by releasing signaling molecules to reorganize the stroma (19). The rigid and 
fibrous PDAC stroma can in combination with high concentrations of hyaluronan increase the 
interstitial fluid pressure, resulting in compression of blood vessels and reduce perfusion leading 








 Production of the structural framework by 
synthesis of ECM proteins. 








Phagocytosis of pathogens and apoptotic cells, 
presents antigens from digested cells. 
 
Dendritic cells 




One of the first responders to inflammation in 
tissues. Eliminates microbes by releasing anti-
microbial substance or phagocytosis. 
Extracellular 
matrix  
Collagen  Connective fibers that strengthen and provide 
structure to tissues. 
Fibronectin  
 
Vital for communication between the intra and 
extracellular environment by binding of integrin 
receptors of the cell surface. 
Laminins  
 
Major component of the basal lamina, crucial for 





Enzymes that can degrade the ECM. Important 
for proliferation, migration, and differentiation. 
Signal molecules 
               
Cytokines 
  
Signaling molecules produced by cells for 
specific biological functions. 
Chemokines  Small molecules that can induce chemotaxis of 
immune cells.  
Table 1.1 Different components of the tumor stroma. 
 
Pancreatic stellate cells (PSCs) are the most important cell type mediating  the dense desmoplasia. 
PSC are classified as myofibroblast-like cells and their main function is to regulate the change in 
extracellular matrix proteins to ensure a secure and normal stroma structure, meaning the PSCs 
can synthesize different ECM proteins as well as matrix metalloproteinases and their inhibitors 
(21). The interaction between PSCs and tumor cells mutually benefit both. Tumor cells increase 
proliferation, ECM synthesis and the migration in PSCs, while PSCs increase the proliferation and 
migration in the cancer cells. PSCs also increase invasion potential and inhibit apoptosis. This 
strengthens the hypothesis that the significance of the stroma is much more than just to provide a 
framework and structure for inflammatory cells and cancer cells (22,23).  
 
In tumor development, PSCs and other cell types are stimulated to become cancer associated 
fibroblasts (CAFs). The primary role of fibroblast is tissue remodeling and regeneration. This is a 
highly regulated procedure, leading to programmed cell death of the fibroblast after completion of 
its tasks or the return to a dormant state (24). The fibroblast function in cancer can be altered, 
producing CAFs that are not highly regulated and are tumor promoting. Tumorigenesis can be 
enhanced by CAFs by stimulating the surroundings to an oxygen-rich, pro inflammatory and 
immunosuppressive microenvironment (25). Challenges emerge when trying to determine the 
biological origin to CAFs, due to a lack of specific biomarkers. Most commonly hypothesized, 
activated fibroblasts in local tissues develop into CAFs during wound healing (26). Mesenchymal 
stem cells derived from bone-marrow can be activated by transforming growth factor β  (TGF-β1) 
and induce the transformation into CAFs (27). The epithelial-mesenchymal transition (EMT), 
where cells lose their polarity and their cell-to-cell adhesion gain the ability to migrate and assumes 
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a mesenchymal cell phenotype (28), allowing the epithelial cells to become fibroblasts. In this 
hypothesis, epithelial cells undergo a specialized EMT where they take on the characteristics of 
mesenchymal cells and transdifferentiate into activated myofibroblasts (29,30). This shows that 
the heterogeneity of CAFs can be explained by the different origins they derive from and will then 
be regulated by different factors. The function of the CAF, regardless where it originated will be 
different between pathological stages and will undergo dynamic changes during tumor progression 
(31). 
 
Inflammatory CAFs (iCAFs), myofibroblastic CAFs (myCAFs) and antigen-presenting CAFs are 
three subtypes of CAFs suggested within PDAC. iCAFs and myCAFs are hypothesized to 
differentiate from quiescent fibroblasts. MyCAFs are suggested to require tumor interaction for 
formation and express high levels of α-smooth muscle actin (α-SMA) (32). Depletion of (αSMA+) 
myofibroblast can lead to a poor prognosis. It is hypothesized that the fibrosis associated with type 
I collagen and myofibroblast makes up a protective response from the host, rather than supporting 
the tumor growth. Myofibroblast is a major contributor of the type I collagen in the stroma, and 
extensive ECM remodeling is associated with myofibroblast depletion with a decrease in tumor 
stiffness (33,25). iCAFs are located more distantly away from the tumor, and when induced by the 
tumor cells, express high levels of inflammatory cytokines, most notably interleukin-6 (IL-6) (32). 
iCAF-secreted IL-6 promotes malignancy by EMT activation (34). apCAFs express both low IL-
6 and αSMA. While it expresses MCH class II molecules with the capability to present antigens 
to CD4 positive T-cells, they cannot induce T-cell proliferation (35). Rather than being an endpoint 
for differentiation, it is suggested that all three subtypes of CAFs can interconvert, depending on 
culture conditions and location in the tumor, supporting the hypothesis of interconvertibility 
between the CAF subtypes (36). 
 
In general, PDAC tumor cells (and subpopulations of CAFs) establish an immunosuppressive 
microenvironment to evade immune surveillance by secretion of immunosuppressive chemokines 
and cytokines and recruitment of regulatory immune cells (37). The tumor microenvironment 
contains several types of immune cells, including macrophages, T-cells and dendritic cells. Tumors 
can release colony-stimulating factor-1 (CSF-1) to educate macrophages to promote tumor growth. 
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Previous studies show that there is a correlation between high volume of tumor associated 
macrophages (TAM) and poor prognosis, meaning increased TAM density is associated with 
advanced tumor progression (38). However, the loss of macrophages through inhibition of CSF1 
receptor relates to T-cell activation and tumor regression. The tumor stroma reverts from an 
immunosuppressive environment, resulting in a marked increase in CD8+  cytotoxic T-cells and 
more responsive to therapies (39). Patients with an increase in effector CD4+ T cells and CD8+ 
T-cells show significantly increased survival (40). The release of interleukin-6 increase the 
inhibition of dendritic cell maturation and promotes a progression to a metastatic tumor phenotype 
(41). The maturation of dendritic cells is necessary for T-cell activation by providing a co-
stimulatory signal. Dendritic cell maturation is common within tumors but is inadequate to create 
a potent immunity(42). This indicates that both immunosuppressive immune cells population and 
the levels of immunogenic cells need to be considered to improve patient survival (43). 
 
1.2.1 Non cellular stromal compartments  
As described above, the tumor stroma consists of different kinds of fibrous connective tissue. Non-
cellular constituents of the tumor that exhibit a tumor promoting effect are different types of 
collagen, hyaluronan and laminin. Mechanical properties and stiffness of the ECM is an important 
factor for cell migration speed (44) and can even dictate cellular migration, showing that the ECM 
is not only a track for migration (45). Type I collagen is a defining feature of PDAC with 
pronounced fibrotic reaction (33). Normally the isoform in healthy tissue is a heterotrimer of two 
α1(I) and one α2(I) chains (α12α2) (46). In carcinomas, a homotrimer of  type-I collagen can often 
be observed, which can be degraded and reorganized by collagenases secreted by CAFs. Type I 
collagen can assist the tumor, by increasing proliferation (47), aid migration (48) and create a 
barrier for invasion. Collagen can also promote invasion by induction of the epithelial-
mesenchymal transition (49). Zinc finger transcription factors can suppress different genes that 
play a key role for the epithelial phenotype (50). When type I collagen interact with PDAC, SNAI1, 
a zinc finger transcription factor is induced by TGF-β1 (51). TGF-β1 is found to be frequently 
overexpressed in PDAC and often associated with an advanced tumor state (52). Collagen 
additionally increase the expression of membrane type 1-MMP, which induces high mobility group 




Hyaluronan can promote tumor progression at high concentrations (54). Healthy tissues regulate a 
tight balance of degradation and synthesis. In the desmoplastic stroma of PDAC, the content of 
hyaluronan is the highest compared to other tumors (55). It might also have an antiapoptotic effect 
and induce chemotherapy resistance (56). Laminins are proteins in the ECM and a major 
component of the basal lamina. They are heterotrimeric proteins that contain an α-chain, a β-chain, 
and a γ-chain, and the combination of the different chains determine the different laminins (57). 
LAMB3, a laminin subunit has been shown to be expressed at a higher rate compared to normal 
pancreatic cells. Both in vivo and in vitro experiments show that LAMB3 activates the P13K/Akt 
signal pathway, leading to an increase in cell invasion and migration  (58). 
 
Figure 1.1 – Comparison of non-malignant stroma and tumor stroma. Nonmalignant stroma 
consists of an elastic ECM with different types of immune cells, mesenchymal stromal cells 
(MSCs) and fibroblasts. The stroma supports the epithelial tissue, with its cells in a quiescent state. 
The stroma cells maintain homeostasis in both the epithelial compartment and in the ECM. Cancer 
cells can activate the stromal components, making the ECM fibrotic and rigid by altering the forms 
of connective fibers. Activated fibroblasts can increase proliferation and can promote resistance to 
therapies. Fibroblast activated by the tumor microenvironment are known as CAFs. The stroma 




1.3 Pre-clinical models 
Decades of research have provided insights into the development and pathology of PDAC. 
However, the relevancy of these pre-clinical models should be questioned as the models do not 
truly reflect the environment and structural properties of pancreatic tumors. Development of novel 
cancer treatments can take up to a decade and is very expensive, and most drugs still fail in clinical 
trials.  Resultingly, expansion of existing or development of innovative pre-clinical models should 
be the priority to bypass the current issues of translatability of oncology research (59,60). This is 
especially the case for pancreatic cancers, as the results from previous pre-clinical models do not 
translate well enough to clinical trials.  
 
So why do pre-clinical models for PDAC fail? Even though nearly all PDAC tumors have mutation 
in the K-Ras gene, there is a large heterogeneity between different tumors and within a tumor that 
makes it difficult to establish a sturdy model that covers all the variation observed. PDAC cancers 
also show mutational heterogeneity in the KRAS gene within the same tumor (61). Since most of 
the tumor volume is comprised of fibrous stroma, using pre-clinical models that include host-
derived fibroblasts and considers the stroma could be more productive. Shifting the focus from 
tumor cells themselves to fibroblasts could result in better pre-clinical models that better reflect 
the tumor microenvironment in PDAC. Pre-clinical models are essential for translation cancer 
research and precision medicine. Commonly used pre-clinical models include both in vitro models 
(2D cultures and 3D models) and in vivo models (patient derived xenograft).  
 
1.3.1 Patient-derived cell lines  
One of the first pre-clinical models employed in the study of PDAC were immortalized cancer 
cells from patients, with the first pancreatic cancer cell line developed in the 1960s (62). Over the 
years 20 different PDAC cell lines have been established from primary tumors. Previous studies 
have reviewed the different cell lines and the differences in genotype, phenotype, origin and the 
tumorigenic properties (63). Cancer cells from primary tumor lose their normal cellular 
interactions and do not preserve the original tumor architecture. When cancer cells are cultures in 
non-physiological environment the genetic changes could result in cells that do not reflect the 
originating tumor genetics (64). A major limitation with using patient-derived cell lines is cross 
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contamination by other cell lines or microorganisms without the handler’s knowledge (65). 
Patient-derived cell lines are most commonly studied using 2D cultures. In 2D cultures, cells grow 
on the surface of adherent culture flasks or petri-dishes and are used for performing functional 
tests and assays for simple drugs tests.  2D cell cultures from pancreatic cell lines are inexpensive 
and easy to work with. They do however, come with some significant limitations; the key 
characteristics of tumors are not maintained and the 2D cultures lack the stroma and its components 
that is present in a PDAC tumor in vivo. As a result, different responses to drugs or other signals 
are not realistic. 2D cultures also come with another limitation. On a flat 2D surface the cells have 
access to  unlimited supplies of oxygen and nutrients from the medium, something that is not the 
case for a tumor (66,67). 
 
1.3.2 Patient derived xenograft  
Patient derived xenograft (PDX) was developed to better simulate the complex microenvironment 
of tumors and understand what drives tumor progression. Immunocompromised mice are used for 
engraftment of tumors. Single-cell suspension or solid tumor pieces are obtained from the original 
tumor by biopsy or surgery, then injected either under the skin (subcutaneous) or in the organ the 
tumor derived from (orthotopic). The tumors are able to develop in the mice without the immune 
system destroying it. This is used to study disease development and testing of anti-tumor drugs 
(68). However, most of the time the engraft tumor fail to reflect its original tumor properties (69). 
This method is very expensive compared to more simplistic models, since the take rate is often 
low and the time needed to establish the method is lengthy. Since the method requires 
immunodeficient mice it lacks the functional elements of the immune system. Models using PDX 
have shown that the patient-stroma in tumor xenografts is quickly replaced with murine stroma 
(70), which will result in a change in ECM composition and loss of fibroblast heterogeneity. The 
treatments on immunodeficient mice also often does not work in humans, due to the different 
immune microenvironment. However, the development of PDX was a major milestone in 




1.3.3 3D growth models 
As described before, 2D models do not resemble the physiology, structure, and function of the 
tumor microenvironment (TME) in vivo, nor does it consider the complex interactions between the 
ECM and tumor cells and lacks the intra-tumoral gradients. Therefore, the development of more 
advanced 3D models seem inevitable (73). 3D models can be used to overcome the simplicity and 
limitations of these models and be a bridge between in vitro and in vivo models. The main 
advantage of 3D cultures compared to 2D is that it simulates the tumor microenvironment more 
accurately due to the cell-to-cell interaction and the interaction between cells and ECM, while also 
recapitulating the signaling and differentiation of cells (74,75). Growing cells in a 3D environment 
changes both proliferation and morphology. By growing cancer cell lines in a 3D, the morphology 
of the cells are more reminiscent of the tumor origin (76,77). 3D cultures also make the tumor 
more resistant to chemotherapeutics. The lack of penetrative ability of the drug can result in 
neoplastic cells in the core of the tumor being left untreated or the intertumoral heterogeneity 
causes resistant phenotypes to emerge and proliferate (78,79) As the models increase in 
complexity, more stromal and non-stromal components can be added to represent the tumor 
microenvironment as accurately as possible.  
 
Figure 1.2 -Modelling the TME. Schematic representation of the major pre-clinical models and 
bio-fabrication techniques (a-f) employed to recapitulate TME complexity. For each model 




An important aspect of the different pre-clinical models is how well they recapitulate the ECM 
(80). Figure 1.2 shows advantages and limitations of different pre-clinical models used for 
modelling the TME. 3D spheroid models create a cluster of cells in uniform or heterogeneous cell 
populations with similar limitations for oxygen diffusion to the center that leads to an apoptotic 
core. This resembles the chemotherapy-resistant and hypoxic core of PDAC tumors (81). By 
including stromal components such as PSCs into spheroid models have shown to lead to the 
production of desmoplastic reaction, with tumor cell morphology and tissue architecture (82). The 
cells produce their own ECM which in turn limits the control over the 3D culture environment 
(83). Scaffold-based 3D models are a more complex model that resemble a natural ECM structure 
with fibers and pores. The most common use of a scaffold-based 3D models is Matrigel®, which 
consists of a gelatinous protein mixture that functions as a reconstituted basement membrane, is 
used frequently for stem cell-based differentiation (84). Differentiation can be improved by 
selection of optimal ECM components (85) e.g, by using ECM derived from decellularized organ 
that maintain organ-specific features. The use of bioprinting can create a tissue specific TME and 
is used as a model for several cancer types. However, there is no model for PDAC using bioprinting 
(86). 3D models can be in both static and dynamic conditions. Dynamic conditions are a better 
representation of human physiology, and development of new models could be beneficial in 
optimizing treatments. Microfluidic chips can be utilized as bioreactors to create a uniformly-sized 
spheroids (87) or to guide cell migration by using composite hydrogel microfibers (88). 
Microfluidic devices have demonstrated the ability to modify multiple microenvironment to study 
tumor development or metastasis within the same device (89). Organ-on-a-chip integrated with 
microfluidics have been designed for fine tuning of the microenvironment by altering different 
physical or biochemical signals, and eventually with the complexity of an entire organ. This aspect 
of studying biomolecular characteristics of PDAC appears promising, and conceivably be used for 







However, 3D cultures still come with some limitations: These include reproducibility between 
different types of scaffolds, and even between different batches of same scaffold type. 
Additionally,  some 3D gel cultures require precise monitoring and stable conditions of 
temperature and pH, , making these cultures more difficult to use and expensive than other culture 
methods. (91). Current 3D models are simplistic and do lack phenotypic similarity and 
heterogeneity. 3D models are expensive compared to 2D models and scaling up the complexity is 
challenging (92). Of note, even the most complex 3D models still fail to reconstitute the many 
features of living organs that determine their function, such as the intricate active 
microenvironment and interface between tissues (93). The perfect model does not exist and needs 
to be tailored to its specific purpose or application. 
 
The 3D model system utilized in these experiments is an expansion of  a previously described pre-
clinical model using decellularized porcine small intestine and pancreas as biological scaffolds 
(94), that preserve the native ECM and can potentially reflect the complex three-dimensional ECM 
composition more accurately. Providing a flexible, biological relevant system that accentuates the 














Pancreatic ductal adenocarcinoma (PDAC) is characterized by late-stage detection, vague or no 
symptoms, low responsiveness to treatments and high mortality. While treatment of other cancers 
has improved markedly during the last years, 5-year survival of PDAC patients is still poor. Recent 
research has emphasized the role of tumor stroma, and its importance in impeding the efficacy of 
treatments and accelerate tumor progression.  Innovative pre-clinical models, which take the 
tumor/stroma interaction into account, are urgently needed. To be able to model and understand 
the complexity of PDAC, we seek to establish a novel 3D culture platform for PDAC based on 
decellularized biological scaffolds with these aims:  
 
• Production of decellularized porcine scaffolds for 3D culture. 
 
• Validation and optimization of a novel 3D model system for PDAC based on different 
types of decellularized porcine scaffolds. 
 










3 Materials and methods 
3.1 Cell culture  
All experiments done within this project were performed with established cells lines. As PDAC 
cell lines, PANC-1 (ATCC CRL-1469), MIA PaCa-2 (ATCC CRL-1420) and BxPC-3 (ATCC 
CRL-1687) cells were used. Furthermore, we used the human pancreatic stellate cell line HPaSteC 
(ScienCell Research Laboratories) kindly provided by Caroline Sophie Verbeke (Institute of 
Clinical Medicine, University of Oslo). 
All cell culture work was done in a laminar flow cabinet using one time use sterile equipment. 
Cells were grown in a 75 cm2 tissue culture flask (VWR International, LLC., Radnor, PA, USA) 
and incubated at 37℃ with 5% CO2. PANC-1 was grown in Dulbecco's Modified Eagle Medium 
(DMEM) high glucose medium (Sigma-Aldrich, Germany) with 1% L-glutamine, 10% fetal 
bovine serum (FBS) and 1% pyruvate. They were split in a 1:5 ratio 2-3 times a week. 
 
 MIA PaCa-2 was grown in DMEM high glucose with 2% L-glutamine, 10% FBS, 2.5% horse 
serum and 1% pyruvate. They were split in a 1:10 ratio 2-3 times a week.  
 
BxPC-3 was grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich, 
Germany) with 2% L-glutamine, 10% FBS and 1% pyruvate. They were split in a 1:4 ratio 2-3 
times a week. 
HPaSteC was grown in DMEM high glucose medium with 1% L-glutamine, 10% FBS and 1% 
pyruvate. They were split in a 1:5 ratio 2-3 times a week.’ 
 
Cells were harvested by removing the medium, washing the cells with phosphate-buffered saline 
(PBS) and adding 20% of trypsin. After 5 minutes incubation at 37℃ all cells can be collected in 






3.2 Lentiviral Transduction of miRFP670 
Transduction is the process of introducing DNA or RNA from a foreign source into a cell by using 
a viral vector. Lentivirus, (a type of retrovirus) can permanently integrate a gene into the genome 
of the host cell. Viruses are often produced inside human embryonic kidney cells (HEK-293T) by 
transfection of multiple vector plasmids. As the technique has developed over the years, so has the 
safety of lentiviral transduction. Three generations of packaging lentiviral plasmids for safety have 
been developed, where the first generation is no longer in use. Lentiviral transduction require three 
major genes; gag, pol and env. Gag is the gene responsible for matrix proteins and a protective 
core, the pol gene is for enzymes including reverse transcriptase and integrase which are necessary 
for genomic integration, while the env gene encodes for surface glycoproteins that enable cell 
entry. Regulatory genes and accessory genes are also commonly used, but are not as essential. The 
second-generation packaging system uses multiple plasmids to deliver the essential genes and 
excludes the regulatory genes. The third generation also uses multiple plasmids but also contains 
a modified transgene plasmid, making it self-inactivating and almost entirely eliminates the 
possibility for hazardous lentiviral recombinant events. This does however result in a lower viral 
yield (95,96). 
 
3.2.1 Plasmid isolation 
To enable confocal imaging of different cell types, pancreatic stellate cells needed to be transduced 
with a fluorescent reporter. miRFP670, a near-infrared fluorescent protein was chosen. As a first 
step, the reporter plasmid must be produced. An agar swab with NEB stable bacteria containing 
the plasmid for pLenti6.2_miRFP670 were re-cultured in a flask with LB broth and incubated for 
16 hours at 37℃. The plasmids were isolated using the HiSpeed Plasmid Maxi Kit (Qiagen, Venlo, 
The Netherlands). The isolation was done according to the manual. Lentiviral vectors were 
synthesized using 3 different plasmids; pLenti6.2_miRFP670, pMD2.G and psPAX2. pMD2.G 
works as a VSV-G envelope expressing plasmid (spike G glycoprotein), while psPAX2 encodes 
gag and pol genes. These are packaging plasmids necessary to produce lentiviral particles. This 
will produce lentiviruses capable of miRFP670 transduction. The pLenti6.2_miRFP670 plasmid 
was kindly provided by Vanessa LaPointe (Addgene plasmid # 113726) 
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3.2.2 Production of miRFP670 virus particles 
A total of 4*106 HEK 293T cells were seeded on a 10 cm cell culture petri dish (Thermo Fisher 
Scientific, Waltham, MA, USA) with 10 ml of DMEM +10% FBS. The cells were incubated at 
37℃ for 16 hours. To improve the transfection of the HEK 293T cells, 23µM chloroquine was 
added to the cells before the lentivirus production and incubated for 5 minutes at 37℃.  To produce 
lentiviruses capable of miRFP670 transduction, A mixture of 971 µl of filtered MilliQ H2O, 
267mM CaCl2, 9µg pLenti6.2_miRFP670, 13.1 µg of psPAX2 and 1.7 µg pMD2.G was prepared, 
to a total of 1500 µl. 1500 µl of 2X Hepes buffered saline was then added and immediately air 
bubbled for 30 seconds using a 2 ml autopipette. The mixture was carefully added to the HEK 
293T cells dropwise until it covered the whole plate. The plate was then incubated at 37℃ for 16 
hours. After 16 hours the medium was changed to DMEM with 10% FBS and incubated at 37℃ 
for 8 hours. To provide higher transduction efficiency, the medium was changed to DMEM with 
30% FBS and incubate for 24 hours at 37℃. The medium from the plate (now containing 
lentiviruses) was collected and filtered through a 0.2-micron filter (VWR International, LLC., 
Radnor, PA, USA) to remove cellular debris. For a second round of virus production, 6 ml of 
DMEM medium with 30% FBS was added to the same plate and incubated for 24 hours. The 
previous step was then repeated.  
 
To determine viral titer, 100 x 103 HEK 293T cells were seeded per well of a 6-well plate (Thermo 
Fisher Scientific, Waltham, MA, USA) and incubated for 24 hours at 37℃. A ten-fold serial 
dilution was performed (total volume =1 ml). The medium from the HEK 293T cells was removed 
and replaced with the dilutions + 0.27µM of polybrene and incubated for 24 hours at 37℃. The 
medium was replaced with 1ml fresh DMEM and incubated for another 24 hours at 37℃. Cells 
were harvested and filtered through a 40nm strainer (VWR International, LLC., Radnor, PA, USA) 
and were resuspended in flow buffer (PBS containing 1% bovine serum albumin) and analyzed 
using the BD Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA). The functional 
titer was determined with a positivity below 10% and assumed 1 positive cell = 1 viral particle. 
Estimated viral titer = 300*103 transducing units/ml. The medium with the viruses was frozen and 




3.2.3 miRFP670 transduction of pancreatic stellate cells (HPaSteC) 
18*103 of HPaSteC were seeded per well of a 6-well plate. They were incubated for 8 hours until 
the cells attached to the plate.  The medium with viruses was thawed and added to one of the wells 
with a multiplicity of infection of 50, meaning 50 lentiviral particles were added per cell of 
HPaSteC. The plate was incubated at 37℃ for 16 hours. The medium was then removed and 
replaced with fresh DMEM medium. The medium was changed and replaced with fresh medium 
every 3 days until the cells were fully confluent. For selection of successfully transduced cells, 
puromycin was then added into the wells in a concentration of 64mM. The plasmid for miRFP670 
contains a gene for puromycin resistance, so cells that have taken up the plasmid will be resistant 
to puromycin. When all the cells in the control well without added viruses had died the transduced 
cells were expanded into a 75cm2 flask.  
 
3.2.4 Purification of miRFP670 expressing HPaSteC with FACS 
Since puromycin selection does not provide a pure population of miRFP670 expressing HPaSteC 
cells, fluorescent activated cell sorting (FACS) was performed to purify a cell population into a 
phenotype-based cell population. In our case, miRFP670 positivity. The cells were cultured to 
around 90% confluency in a 75cm2 flask. Cells were harvested and filtered through a 40nm strainer 
then the cells were resuspended in flow buffer at a concentration of 5 million cells per ml. Sorting 
was done by a trained employee from the Flow cytometry Core Facility at University of Bergen. 
miRFP670 positive cells were collected into a 15 ml falcon tube, centrifuged, and seeded in an 
appropriately sized cell culture flask.Flow analysis was performed using the BD Accuri C6 flow 








3.3 Confocal microscopy  
Confocal microscopy differs from a conventional microscope. Both use the reflected light or 
fluorescent light to image the sample, but in confocal microscopy the excitation beam is focused 
on a small spot inside the sample. By using small pinhole aperture, only the light emitted from the 
focal spot of the excitation beam passes through and only that light is detected. The scattered light 
outside the focal point is blocked, allowing for a sample to be imaged at one point at a time (97). 
A spinning-disc confocal microscopy utilizes multiple pinholes or slits, so the fluorescence is 
exited and imaged at several point at the same time. When the disc is spun an image is formed by 
scanning the sample in rows through the pinholes. The spinning disc greatly increases the image 
acquisition speed, allowing for imaging of live specimens. This method allows for great variation 
and optimalization by changing the diameter of the pinholes, the distance between the holes or the 
rotational speed of the disc. The method however, does not give as high resolution as other methods 
(98). Using cell lines with fluorescent genes transduced works great together with spinning-disc 
confocal microscopy, even multiple cell lines can be imaged together with different fluorescent 
reporter genes. However, the cell line needs to be transduced for this to work optimally. This 
method works best for established cell lines and is easily reproducible.  
Green fluorescent protein (GFP) and near-infrared fluorescent protein (miRFP) are such proteins.  
GFP, originally isolated from the jellyfish Aequoria Victoria is excited at ~470nm and emits at 
~510 nm. GFP is the most used fluorophore, and different variations of color and altered 
excitation/emission wavelengths (99). miRFP670 is a near-infrared protein derived from the 
bacterium Rhodopseudomonas palustris, that is excited at 642nm and emits at 670nm. 
 
The Dragonly 505 confocal spinning disk system (Andor Technologies, Inc, Belfast, Northern 
Ireland) with an iXon 888 Lide EMCCD camera was used to image all the scaffolds. All images 
were captured using the FUSION imaging software (Andor Technologies, Inc, Belfast, Northern 
Ireland). 10x objective was used for all experiments.  Z-stack depth was selected between 60-250 
µm depending on scaffold thickness, with a 2µm step size. To provide a sincere overview of the 
entire scaffold, three random areas per scaffold were imaged.  
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3.3.1 Processing of data from confocal microscopy 
The confocal data was processed using the Imaris cell imaging software. (Oxford instruments, 
United Kingdom) The fluorescent signal of the cells on the scaffold is used to display the total 
surface volume covered by the cells. A minimal signal threshold and size of the signal had been 
set to remove background signal from the scaffolds and other noise. The volume data was extracted 
from the Imaris software as an Excel document and can be plotted in GraphPad Prism.  
 
3.4 Decellularized porcine scaffolds 
Porcine intestine and pancreas were collected at the Laboratory Animal Facility, Department of 
Clinical Medicine, University of Bergen. The production of decellularized scaffolds from those 
tissues has been previously described (94). 
 
3.4.1 Decellularization of intestinal scaffolds (SISser) 
The small intestine is composed of three layers. Surrounding the lumen is the mucosa, followed 
by the submucosa and the serosa on the outside. The intestine was cut in approximately 10 cm 
long pieces, the lumen flushed with tap water and inverted using long forceps. The mucosa layer, 
which is now on the exterior side, was scrapped off using forceps resulting in the submucosa as 
the outer layer and serosa as the inner layer. The intestinal tissue pieces were incubated for 24h in 
PBS + 1% P/S at 4℃. The intestinal pieces were then washed 3 times with 1x PBS. 86.6 mmol/L 
of sodium deoxycholate (Sigma-Aldrich, Germany) (DOC solution) was freshly prepared and kept 
cold. For decellularization, the intestinal pieces were filled with DOC solution and sealed on both 
sides with plastic clamps, incubated in DOC solution for 1.5 hours at 4℃. One of the sides was 
opened, refill with PBS and incubated in PBS for 1hour at 4℃. Then the part of the intestine that 
was not decellularized was removed. The intestinal pieces were then incubated for another hour in 
PBS + 1% Penicillin. The PBS + 1% Penicillin was changed 5 times and stirred at 4℃ for 16 
hours. The intestinal pieces were then incubated for 2 hours at 37℃ in DNase 1 solution (166 
µg/ml; Sigma-Aldrich - Germany) in warm PBS with calcium (0.12 mM), magnesium (0.12 mM) 
and 1% Penicillin. The pieces were then put into cold PBS and the PBS was changed 3 times, then 




3.4.2 Decellularization of pancreatic scaffolds (PanMa) 
Production of decellularized porcine pancreas scaffolds is more challenging as a result of the large 
amount of digestive enzymes. Therefore, the dissection of the pancreas needs to be done quickly 
and preferably at low temperatures. The pancreas is removed en bloc with spleen and the ductal 
connection to the intestine. All connective tissue is then carefully removed. The duct which is 
connected to the intestine is carefully exposed and canulated with a 22G needle. Furthermore, 
veins/arteries from the spleen to the pancreas are used for cannulation with 18G needles. 
Cannulation of the duct and vessel systems is necessary in order to allow proper decellularization. 
The decellularization and sterilization process for the pancreas is basically the same as for the 
small intestine (described in section 3.4.1).  
 
Figure 3.1 - Explantation of porcine pancreas.  The Figure shows how the pancreas is extracted. 
3.a shows the pancreas before it was cut out, b shows the pancreas with the spleen connected with 
b1 showing the vein connecting the pancreas and spleen. This is the vein used for cannulation as 
described before. c shows the different ducts used for decellularization. d shows the decellularizing 




3.4.3 Mounting of scaffolds  
In order to enable 3D culture of cells on the decellularized tissues, the scaffolds need to be kept 
bow-taut on a supporting structure. To this end, so called “cell crowns” were designed and 3D 
printed, using biocompatible materials. The scaffolds are attached on the crowns like the skin of a 
drum. Sterile scaffolds were placed on a 10 cm petri dish and flattened using forceps. The intestinal 
tissue was cut from one opening to the opposite using a scalpel blade. The scaffold was opened 
and carefully flipped using forceps, making the submucosa layer facing up. The scaffolds were cut 
into smaller squares, between 1-2 cm2. The bottom part of the crown was placed on top of the 
scaffold and carefully mounted, the crown was then turned, and a ring was placed around it to 
secure the scaffold. Each complete crown was added to a 12-well plate (Thermo Fisher Scientific, 
Waltham, MA, USA) containing 1.5 ml medium. 500 μl of medium was added into the center of 
each crown.   
  
Figure 3.2 – scaffold mounted onto a crown. The image on the left shows how the scaffold is 
mounted on top of the crown, with the ring to secure it next to it. the figure on the right shows how 
the scaffolds are flipped prior to imaging. The cells are seeded on the mucosa layer on the inside 
of the crown. The ring is removed, and the crown is placed onto another crown. The scaffold is 
folded down onto the new crown and a new ring is added to secure the scaffold. The figure was 
created in BioRender. 
 
3.4.3 Cell seeding on scaffolds 
Cell were harvested and counted to make sure the starting number of cells was adequate. To ensure 
proper soaking of the scaffolds with medium, scaffolds were prepared at least 24h prior to the start 
of the experiment. The desired number of cells was centrifuged and then resuspended in 500 µl 
fresh medium. The cells were seeded on the inner part of the scaffolds (submucosa for SISser or 
PanMa respectively). Initially, different cell numbers were seeded to determine optimal conditions. 
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3.4.4 Flipping of scaffolds for imaging 
Since the cells were seeded on the inside of the scaffolds, the orientation of the scaffold must be 
inverted before imaging (Figure 3.2), due to the necessity of cell contact with the imaging plate. 
Each crown was transferred to a 10 cm petri dish and the outer ring was removed. The crown was 
moved on top of a new crown and the matrix on the outside of the crown was folded down onto 
the new one. The old crown was removed, and a new ring was added, leaving the scaffold oriented 
with cells located on the outer surface. The crown was moved back to the 12 well plate containing 
medium, and 500 µl of fresh medium was added to the inside of the crown. When the scaffolds 
were imaged, they were transferred to a 6-well plate with sterile forceps containing 1 ml of fresh 
medium. After imaging they were transferred to a new 12-well plate each containing 1 ml of fresh 
medium. The medium in the center of the crown was also replaced by 500 µl of fresh medium. 
The plate was then transferred back to the incubator at 37℃. 
 
3.5 Dynamic cultures 
Monocultures of PANC-1 with a starting number of 50 x 103 cells were seeded on SISser scaffolds 
and incubated in static conditions. After the cells were cultured in static conditions, the scaffolds 
were transferred to a bioreactor, designed by collaborators at the Fraunhofer Institute Wurzburg, 
Germany. The bioreactors were placed into a Simatic HMI incubator for dynamic culture (Figure 
3.3). Flow speed and pressure could either be in a constant flow or sinus rhythm. The scaffolds 
were incubated for either 3 days or 7 days in static conditions before they were transferred to the 
incubator at 37℃. The scaffolds were cultured for a total of 10 days. Flow speed was set to either 
1.5ml per minute or 3ml per minute with a sinus rhythm. After the experiments, the scaffolds were 




Figure 3.3 – Schematic of dynamic conditions. The figure shows the silicon bioreactor connected 
to a peristaltic pump and a medium reservoir in a closed loop. From the reservoir, the pump 
delivers medium to the bioreactor harboring scaffolds mounted onto 3D printed chips.  
 
3.6 Histology  
3.6.1 Fixation  
After the final day of imaging, histological analysis was done. Firstly, the medium within and 
outside the crowns was removed and replaced with PBS. 1 ml was added to the wells and 500 µl 
was added to the center of the crown. The PBS was then replaced with 4% paraformaldehyde 
(PFA) and incubated for 1 hour. The PFA was removed, and the crowns were washed again with 
PBS. The crowns were transferred to a 10 cm petri dish. Using a scalpel blade the scaffold on the 
outside of the crown was cut, releasing a circular field of scaffold containing tissue which was 
removed from the crown. The circular scaffold was divided into two pieces and transferred to 
histological cassettes, then stored in until further processed. 
 
3.6.2 Dehydration and embedding  
The scaffolds were dehydrated using a TP1020 tissue processor (Leica Biosystems, Wentzler, 
Germany) The samples were immersed in 2 changes of 80% ethanol, 2 changes of 96% ethanol, 4 




3.6.3 Mounting of paraffin blocks 
After dehydration, the scaffolds were embedded with paraffin. The scaffolds were placed in a 
metal mold whereby the center of each half of the scaffold was oriented up. Paraffin was added to 
fill the metal mold and subsequently placed on a cold surface to solidify. 
 
3.6.4 Slicing of paraffin blocks 
Before the paraffin blocks were sliced, they were kept in -20℃ for at least 1 hour. The blocks were 
sliced using a RM2155 microtome (Leica Biosystems, Wentzler, Germany). Initially, the blocks 
were trimmed until the surface of the scaffolds cross section became visible on the paraffin block. 
Then 5 µm thick sections were cut and transferred to a 42℃-water bath. The slices were collected 
to a microscopy slides (VWR International, ltd., Radnor, PA, USA).  The sections were let to 
completely dry before staining. 
 
3.6.5 Hematoxylin-Eosin (H&E) staining 
H&E staining was done to provide a comprehensive picture of the tissue’s microanatomy. 
Hematoxylin stains the nuclear components dark blue or purple while eosin stains collagen and 
elastic fibers in a pinkish color.  Before staining the hematoxylin was filtered to remove aggregate 
and an eosin working solution was prepared. 14.5mM eosin Y was diluted in 100 ml of distilled 
water and 400 ml of 96% ethanol. This eosin Y stock solution was further diluted by adding 50 ml 
of the eosin Y stock solution to 150 ml 80% ethanol + 87 mM glacial acetic acid (Sigma-Aldrich, 
Germany)  
 
Deparaffination and rehydration was achieved by: 2x10 minutes incubation in xylene (Sigma-
Aldrich, Germany), 2x5 minutes incubation in absolute alcohol, 1x5 minutes incubation in 96% 
alcohol and 1x5 minutes incubation in 70% alcohol. After a brief wash in MilliQ water, sampled 
were incubated in Harris hematoxylin solution (CellPath, United Kingdom) for 2 minutes, 
followed by 10 minutes of washing in warm tap water. Samples were rinsed with 10 dips in 95% 
alcohol and counterstained in eosin working solution for 1 minute. Finally, sampled were 
dehydrated by 1x5 minutes 95% alcohol and 2x5 minutes of absolute alcohol incubations. Samples 
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were cleared in 2x5 minutes xylene. Xylene based mounting medium (Sigma-Aldrich, Germany) 
was added and the samples were protected by cover slides. 
 
3.6.6 Imaging of stained slides 
The stained histology slides were imaged using a VS120 S6 slide scanner (Olympus Life Science, 
Waltham, MA, USA). Multiple fields of view were captured using the VS-ASW S6 software 
(Olympus Life Science, Waltham, MA, USA) and assembled to get high a resolution image of the 
tissue on the slide. An overview of the slide was acquired at 2x magnification and the parts of the 
slide with tissue were imaged at 20x magnification.  The images were processed using QuPath 
version 0.2.3 (100). 
 
3.7 Treatment with gemcitabine.  
To investigate the effect of the chemotherapeutic drug gemcitabine (GEM), 25 x 103 PANC-1 cells 
were seeded on SISser scaffolds and incubated for 10 days. Various concentrations of GEM 
(Fresenius Kabi oncology Ltd, United Kingdom) 10 µM, 100 µM or 1000 µM were added to the 
cells and incubated at 37℃ for 72h. The medium was changed every 24h and replaced with fresh 
DMEM medium containing GEM. The cells were monitored during the treatment using confocal 
microscopy. Signal quantification and processing was done using the Imaris software as described 
in section 3.3. 
 
3.8 Statistics  
Statistical analysis results were expressed as mean values± standard deviation. Comparisons 
between groups were made using unpaired T-test. Differences where p<0.05 were considered as 
statistically significant. Statistics were analyzed using GraphPad PRISM®v8.4.2(GraphPad 





4.1 3D monocultures of PDAC cells on decellularized porcine intestine (SISser) 
The aim of this project is to apply a previously described 3D culture system based on decellularized 
porcine tissue to pancreatic cancer research. We used 3 different established cell lines to establish 
and optimize the model system by determining variation of growth and the invasive potential of 
the different cell lines. For better understanding of the different cell lines, various cell numbers 
were tested. Elucidating comprehensive insights from PDAC cell lines will make the use of patient 
material more predictable, which is much rarer and is not as readily available as established cell 
lines. PDAC cells were seeded on decellularized intestinal scaffolds (SISser), consisting of the 
submucosa and serosa layer. The PDAC cells were seeded on the submucosa layer. The submucosa 
consists of thick, irregular layers of connective tissue with low immunogenicity, suitable for cell 
adhesion, proliferation, and differentiation. Such materials can be used optimally as scaffolds. To 
follow the development of the cell lines over time without the use of additional dyes, we used GFP 
expressing cell lines. The growth of the cells was monitored with confocal microscopy and 
subsequently, the covered surface volume was determined. The signal from the total surface 
volume is derived from GFP expressing cells, and corelates directly with cell numbers. Using 
Imaris software analysis of the fluorescent signal from the cells, the 3D GFP signal was plotted in 
2D and covered surface volume is quantified. Autofluorescence and artefacts are removed by 
setting intensity thresholds and size limits to the GFP signal. The scaffolds were fixed, stained 
with H&E and histologically assessed after the experiments were completed.  
 
4.1.1 PANC-1 monoculture growth  
Scaffolds were seeded with 6 x 103, 12 x 103, 25 x 103, 50 x 103 and 100 x 103 PANC-1 GFP+ cells 
and imaged with confocal microscopy on day 3, day 7, day 10, day 14 and day 21. On day 21 the 
cells were fixed and assessed histologically by H&E staining. Figure 4.1 A shows the PANC-1 
monoculture grew slowly until a certain confluency then the signal intensity rapidly increased. 
Populations of spherical cells grew dispersed with some areas with more dense concentrations. 
The cells grew until the whole field was confluent. All starting concentrations were confluent by 
day 14, except for 12 x 103. By day 21, several of the starting numbers showed a decrease in 
brightness as seen on Figure 4.1. However, the total surface volume was still increasing as seen on 
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Figure 4.2. A plateau was not observed, and the highest GFP signal intensity was observed at day 
21 with the highest starting number of cells. The histological analysis by H&E staining (Figure 
4.3) show that they grow unevenly with several cell layers covering the top of the scaffold. 
Invasion of cells into the scaffold was mostly observed with the higher starting number of cells 
and observed as low as 25 x 103.  
 
 
4.1.2 MIA PaCa-2 monoculture growth  
Cell cultures of MIA PaCa-2 followed the same experimental set-up as with PANC-1. Figure 4.1 
B shows that the MIA PaCa-2 cells are small and circular, eventually dispersing into several small 
colonies of cells until they merged and covered the whole scaffold. Rapid cellular growth occurred 
and  the cells became confluent by day 7 for all starting number of cells except the lowest, as 
shown on Figure 4.1 A. Figure 4.2 show that MIA PaCa-2 cells reach the signal max by day 7 with 
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a starting number of 50 x 103 cells. The signal then decreased for several of the concentrations, 
and most of them stabilized at day 14. The histological analysis by H&E staining (Figure 4.3) 
shows the MIA PaCa-2 cells were the most invasive, showing high invasion at the lowest 
concentration. MIA PaCa-2 also develop the largest invasive colonies. Multiple cell layers can be 
seen invading, with mostly a single layer on the surface of the scaffold.  
 
4.1.3 BxPC-3 monoculture growth 
Cell cultures of BxPC-3 followed the same experimental set-up as with PANC-1. The BxPC-3 
cells grew into big separate circular colonies as seen in Figure 4.1 C. The colonies of cells 
continued to expand and eventually merged, once the field was confluent. Only the three highest 
concentrations of cells managed to grow to a level where the entire field was confluent. The 
brightness from the cells decreased significantly on the last two imaging days, while the total 
surface volume (Figure 4.2) only decreased a little. Figure 4.2 also shows that BxPC-3 cells 
reached the highest total surface volume at day 10 with the 2 highest starting cell numbers. The 
signal intensity was stable for all starting numbers from day 10 to day 21, with the two highest 
slowly decreasing and the others slowly growing.  The histological analysis (Figure 4.3) by H&E 
staining showed that BxPC-3 cells grew as an even thick layer of cells at the top of the scaffolds 
with an increase in cell layers with higher starting numbers. BxPC-3 cells show very little invasion 
potential. With the highest starting number of cells seeded, large invasion-clusters were observed. 





Figure 4.2 – Quantification of cell growth of PDAC GFP+ cell lines on SISser.  The Figure shows the 
growth kinetics of the different cell lines in different starting number of cells (6 x 103, 12 x 103, 25 x 103, 
50 x 103, and 100 x 103). The cell lines are monitored over 21 days and total volume of the GFP signal is 










4.2 Coculture of PDAC cells and pancreatic stellate cells on decellularized porcine intestine 
(SISser)  
Since PDAC is defined by the desmoplastic stroma, cocultures of pancreatic stellate cells together 
with PDAC cells can provide a more realistic environment than monocultures. With the ability to 
track multiple fluorescently labeled cell lines simultaneously, PDAC cell lines were cultured 
together with pancreatic stellate cells (HPaSteC). The starting number of PDAC cells were chosen 
based on the growth kinetics of the monocultures, so that the cocultures would have similar growth 
kinetics across all PDAC cell lines. PANC-1 and BxPC3 cells were grown in a starting number of 
50 x 103 cells/scaffold together with 12.5 x 103 HPaSteC cells. MIA PaCa-2 cells were grown in a 
starting number of 25 x 103 cells/scaffold together with 6 x 103 HPaSteC cells. For comparison, 
monocultures of all three PDAC cell lines and monocultures of HPaSteC were grown as well. 
Figure 4.3 – H&E-stained slides of monocultures of PDAC cell lines on SISser 
The Figure shows the H&E-stained slides of the different PDAC cell lines, acquired after 21 days in 




The coculture experiments followed the same set-up as the monocultures, with imaging on day 3, 
day 7, day 10, day 14 and day 21, followed by fixation and histologically assessment by H&E 
staining. 
 
4.2.1 Selection of miRFP670+ pancreatic stellate cells for coculture 
To visualize and track multiple cell lines at once, HPaSteC cells- a human pancreatic stellate cell 
line was transduced with miRFP670. By using two different fluorescent reporter genes both can 
be imaged simultaneously. The transduction of HPaSteC is described in Materials and Methods 
section 3.2. 
 
Figure 4.4 show two different flow cytometry analyses with identical set-up. By using gating, 
populations of cells can be isolated into subpopulations. For this experiment, three gates were 
constructed with area of forward scatter FSC on the X-axis and different variables on the Y-axis. 
From left to right, the first panel shows the area of FSC and the area of side scatter (SSC) of the 
cells, so cellular debris could be removed. The second panel shows FSC area and height, so 
doublets could be removed. The third show the area of FSC with the FL-4 channel, a laser that will 
excite miRFP670 within the cells. Higher emitted miRFP670 will result in the cells being located 
higher on the Y-axis. The upper panel shows wild type HPaSteC without miRFP670 transduced, 
showing a miRFP670 positivity ≈ 0%. The second analysis shows the HPaSteC with miRFP670 







4.2.2 Growth pattern of HPaSteC on decellularized porcine intestine (SISser)  
Monocultures of HPaSteC were grown in a starting number of 25 x 103 and 50 x 103 cells/ scaffold 
and grow as dispersed single cells until they covered the whole field. (Figure 4.5 A) The growth 
kinetics between the initially seeded 25 x 103 and 50 x 103 cells/scaffold were minimal. Large 
variations were observed when HPaSteC cells were grown in coculture with PDAC cell lines as 
seen on Figure 4.6. The HPaSteC grown in coculture with PANC-1 grew slowly but steadily over 
the 21 days, while the Coculture with MIA PaCa-2 grew rapidly until day 7 and den rapidly 
declined until the signal almost completely disappeared. HPaSteC cells in coculture with BxPC-3 
grew rapidly until day 10 day and plateaued and grew in densely packed pockets in between the 
BxPC-3 clusters. They also showed similar growth kinetics with the HPaSteC in monoculture, 




4.3.1 PDAC cells + HPaSteC cells 
The morphology of PDAC cell lines grown in monoculture (Figure 4.1) and coculture with 
HPaSteC (Figure 4.6 A) is analogous. The PANC-1 monocultures show similarities with the 
cocultures with HPaSteC. Small, dispersed clusters were observed with low cell numbers until day 
10 and a rapid increase in growth by day 14. MIA PaCa-2 cocultures with HPaSteC grew nearly 
identically with dispersed cell clusters as in monocultures. The monocultures did however become 
confluent sooner (day 7 vs day 10). As the two other cell lines, BxPC-3 cells grew nearly 
identically in monoculture as in coculture by forming large cell clusters that grew slowly until day 





As seen on Figure 4.6 B, the growth kinetics of PDAC cells in monoculture and in coculture with 
HPaSteC are nearly identical. The coculture with PANC-1 and HPaSteC grew a little slower, but 
there was no statistically significant difference between the growth kinetics in monocultures and 
cocultures.  
 
Histological analysis by H&E staining of cocultures from Figure 4.6 C also showed similarities 
from the monocultures (Figure 4.3). PANC-1 + HPaSteC showed similar thick layer of cells on 
top of the scaffolds as seen on monocultures, with more frequent but smaller patches of invading 
cells. MIA PaCa-2 + HPaSteC showed a thin line of cells on top of the scaffold with some cells 
invading as seen on the monocultures. The invasion observed in monoculture is much higher than 
in cocultures. BxPC-3 + HPaSteC showed the similar, even layer of cells on top of the scaffold as 
with monocultures. A slight increase in invasion potential was observed when grown in cocultures. 
In summary: Both growth pattern and growth kinetics are nearly identical. The invasive potential 












4.3 Coculture of PANC-1 and HPaSteC on decellularized porcine pancreas (PanMa) 
By using decellularized porcine pancreas, the ECM composition is hypothesized to be much more 
similar to human pancreatic ECM compared to the ECM of SISser. PanMa harbors organ-specific 
properties and will help to create a more realistic microenvironment. Decellularized porcine 
pancreas can effortlessly be implemented into the model system using the same experimental setup 
as with SISser scaffolds. Due to limited amounts of PanMa scaffolds available, only PANC-1 cells 
were used. PANC-1 cells were seeded with a starting number of 50 x 103 cells/scaffold in 
monoculture and 50 x 103 cells/scaffold in coculture with 12 x 103 HPaSteC cells/scaffold. The 
starting number of cells were chosen according to the experiments performed on SISser.  
Figure 4.7A and Figure 4.7B show that PANC-1 grow nearly identical in monoculture and 
coculture on PanMa scaffolds. Very low numbers of HPaSteC were observed in the coculture, as 
seen on Figure 4.7A. Histological analysis from Figure 4.7C shows that PANC-1 in monoculture 
and PANC-1 + HPaSteC form the same multi-cell layer on top of the scaffold as seen on SISser 




4.4 Comparison of cell growth on SISser and PanMa scaffolds 
Comparing difference in growth patterns and kinetics of different scaffolds with dissimilar ECM 
properties will show the impact of ECM composition on growth. The physical properties, structure 
and composition of the ECM dictate the interactions between the cells and the matrix, and thus is 
vital for cellular behavior. SISser and PanMa have different ECM composition and biophysical 
properties. PANC-1 cells were seeded with a starting number of cells of 50 x 103 cells/scaffold in 
monoculture and coculture. In coculture, 12 x 103 HPaSteC cells/scaffold were added. Figure 4.8A 
shows the growth kinetics for PANC-1 cells grown in coculture with HPaSteC is nearly identical 
on SISser and PanMa scaffolds, while Figure 4.8B shows a signifcant variation between HPaSteC 
on SISser and PanMa. The total surface volume from HPaSteC on PanMa was much lower at the 
start of imaging compared to SISser, even though same cell numbers were seeded. The total surface 
volume of PanMa covered by HPaSteC cells slowly increased until day 10, then the signal 
decreased before almost disappearing completely, while the HPaSteC signal on SISser grew at a 








4.5 Dynamic culture of 3D models 
Since physiological conditions in vivo are not static, a dynamic culture system was tested to 
develop the model system to mimic the microenvironment more accurately. The dynamic 
bioreactor was developed in collaboration with the Fraunhofer Institute (Wurzburg, Germany) and 
described above (Materials and Methods 3.5). To initially assure proper attachment of the cell to 
the scaffolds, PANC-1 with a starting number of 50 x 103 cells were seeded on SISser scaffolds 
and were cultured in static conditions for either 3 or 7 days before transferred into dynamic 
conditions for a total of 10 days with a flow speed of either 1.5ml per minute or 3 ml per minute.  
After the experiments, the cells were histologically analyzed as described in section 3.6. Every 
combination of flow speed and days in static conditions resulted in the same outcome, empty 








4.6 Gemcitabine treatment efficacy 
To examine applicability of our model system for PDAC therapy, we tested gemcitabine treatment 
efficacy. PANC-1 cells were cultured on SISser scaffolds with a starting number of 25 x 103 
cells/scaffold and kept in culture for 10 days. After the cells were allowed to attach to the scaffold 
and grow for 10 days, gemcitabine was added to the cells in a concentration of 10 µM, 100 µM or 
1000 µM. The medium was replaced each day over 3 days with fresh medium containing the 
respective concentration of gemcitabine. The cells were monitored using confocal microscopy 






Results from the GEM treatment (figure 4.9) showed low to no effect. The control cells without 
GEM showed an increase in signal before and after treatment, while the treated cells kept a stable 
signal throughout the treatment. Only the cells treated with the highest concentration (1000µM) 
showed a small decrease in signal. Small differences in morphology are observed. The treated cells 
were smaller and more dispersed due to loss of cell-cell adhesion.  
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5 Discussion  
Due to the dense stroma and limited vascularity, vague symptoms and poor markers, pancreatic 
cancer is one of the most obstinate cancers to treat with the current treatments available. PDAC 
can also be highly invasive, even at early stages of disease development (101). 
A defining feature of PDAC is the dense and fibrous stroma, including an accumulation of collagen 
rich ECM, significant increase in inflammatory cells as well as pancreatic stellate cell (PSC) 
activation and expansion (20). Studying and recognizing the cell-stroma molecular interactions 
could be the key to overcome the therapeutic resistance (102). 
The low effectivity of treatments combined with the disparity in results between pre-clinical 
models and clinical trials concludes that novel or improved pre-clinical model systems considering 
the tumor cells and tumor microenvironment, are required to improve long-term survival in PDAC. 
Our main objective was to provide a better pre-clinical model by expanding and optimizing a 
previously described approach using decellularized porcine scaffolds.  
 
 5.1 Optimization and expansion of the 3D culture approach 
In the present study, we used decellularized porcine intestine and pancreas as 3D scaffolds for 
repopulation with PDAC cell lines. The internal organs of humans and pigs show several 
anatomical similarities. For the small intestine, the structure and microscopic features are 
comparable. There is however some controversy on the cellular similarities (103). 
In the case of the pancreas, function and location in the body is comparable, but is smaller in 
relations to the human pancreas. The human pancreas is divided into the “tail”, “body” and “head” 
of the pancreas while the pig pancreas consists of three lobules. The amount of literature describing 
the detailed anatomy of pig pancreas is limited, making it difficult to conclude how well the matrix 
composition of pig pancreas compares to humans (104).  
 
The adjacent ECM composition of primary tumors varies according to the tissue type. If a pre-
clinical model system does not account for this, the response to therapies will not be consistent in 
clinical use. The use of decellularized tissues as 3D culture scaffolds provide a remarkable ability 
to recreate the native ECM of the original tissue, while maintaining mechanical properties like 
stiffness and microstructures (105,106). In particular, decellularization of pancreas shows a 
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preservation of macroscopic structure as ducts and vasculature, while preserving ECM constituents 
like collagens and elastic fibers (94). Optimalisation of the decellularization process is crucial, 
since exocrine enzymes of the pancreas have a cytotoxic effect (107).   
 
Despite this, the matrix derived from decellularized porcine organs, both SISser and PanMa work 
well as biological scaffolds.  Using decellularized porcine intestine and pancreas as a 3D model 
system, the biological role of the stroma can be better understood and detecting the crucial 
interactions necessary for PDAC development and chemotherapy resistance. Considering the 
importance of the tumor stroma in PDAC, using PanMa scaffold can provide the most realistic 
environment for further research into PDAC development. The system can also be used to test 
sensitivity to treatments and perhaps in the future be expanded to include other types of the tumor 
microenvironment as well. 
 
The production of SISser scaffolds shows good reproducibility between the scaffolds used in these 
experiments and the scaffolds from the Fraunhofer Institute, where they were originally developed. 
Some areas of the small intestine were however, not suitable for scaffold production, notably the 
intestinal parts (ileum) anterior to the large intestine. The tissue was more tough, and difficulty 
occurred when the mucosa layer was to be removed. The production of PanMa requires the porcine 
pancreas to be removed en bloc with the spleen and a part of the duodenum still connected. 
Removing all the connective tissue and cannulating the duct and vasculature proved to be a 
challenge, especially since it had to be done quickly due to large amounts of digestive enzymes in 
the pancreas. 
 
 Further improvements in the crown design could be beneficial. Since the scaffold needs to be 
flipped before imaging due to the necessity of the cells to be in contact with the imaging plate, 
using crowns that remove the need for flipping could reduce the amount of ruined scaffolds and 
the contamination risk during experimentation. Thereby, mounting of decellularized PanMa onto 




An important improvement of the method was achieved by use of cell lines expressing fluorescent 
reporter genes. To establish the culture of pancreatic cancer material on the 3D scaffolds, 
visualization of cell growth is indispensable to understand the dynamics over time. 
It further allows the user to easily and cost effectively visualize cultures of cells, both different 
monocultures and cocultures using confocal microscopy. Different cell types grown in coculture 
are easily distinguishable by using fluorescent proteins that have different excitation and emission 
spectrums. We have used different starting number, using three different PDAC cell lines. This 
allowed us to understand how different cell lines behave in 3D culture compared to 2D and thereby 
infer from those data to the use of patient material. The use of confocal microscopy is of great 
benefit to track already labeled cells. However, this is not feasible for primary tumor material due 
to the cells not being labeled with a fluorescent reporter. Labeling of primary tumor cells is also 
not practical since the cells need to be expanded several times, which would lead to the 
differentiation of the tumor cells. Therefore, a thorough characterization of cell lines is 
indispensable for the use of patient material. 
 
5.2 Monoculture growth on SISser 
The different characteristics of each cell line is easily detected using by their GFP expression and 
imaging using confocal microscopy. The confocal microscopy was shown to work well for 
quantification of cell growth over time. It can be used to determine the duration of the experiment 
and the starting concentration of cells for different cell lines with unknown growth patterns. 
The PDAC cell lines used, PANC-1 MIA PaCa-2 and BxPC-3 displayed unique growth patterns, 
comparable to the growth patterns observed in 2D (108). Studies of growth kinetics of the three 
cell lines show that in 2D cultures the different cell lines proliferate at similar rates, while in 3D 
spheroid cultures there is a large variations between BxPC-3 and two other cell lines (90). The 
morphological differences of PDAC cell lines are also enhanced when cultured in 3D (109). In the 
3D model system using SISser scaffolds, MIA PaCa-2 had the shortest doubling time, followed 
by PANC-1 and BxPC-3. Another interesting aspect was the low growth of the lower starting 
numbers, especially for PANC-1 and BxPC-3. The cells appeared to need a certain concentration 
to proliferate at a high rate. This can be explained by the need for cell-to-cell interactions, which 
have been shown to increase proliferation (110).  
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The different cell lines and starting concentrations reach confluency at different time points. After 
the cells grew confluent the signal often plateaued, then either kept stable or slowly decreased. 
This could be because the cells die and the signal is lost or that the cells invade deeper into the 
tissue. As the GFP signal does not travel very well trough tissue and cannot penetrate through the 
scaffold, it can explain the loss of signal. Most of the signal comes from cells located on the top 
of the scaffold surface, but it is difficult to distinguish between the cell signal from cells on the 
surface or cells that have started to invade the scaffold. The different cell lines also have a different 
invasion potential. MIA PaCa-2 cells have the highest invasion potential, at seen from the 
histological experiments from Figure 4.3 and have the most total signal loss, as seen on Figure 4.2. 
The images from Figure 4.1 show that all 3 cell lines decrease in brightness at the end of the 
experiments, while the signal from PANC-1 and BxPC-3 is stable. This indicates that the 
brightness observed does not equal to total signal measured. These results show that both cell line 
and starting number is important for invasion potential. 
 
5.3 Coculture growth on SISser 
To further expand the 3D culture approach, we performed cocultures of pancreatic cancer cells 
and pancreatic stellate cells. Previous studies have shown that PDAC cells grown with SDF-1-
positive CAFs increase proliferation significantly, impacting malignancy and GEM resistance 
(111). However, in our setting PDAC cells grown with HPaSteC showed no increase in 
proliferation. This might be due to cell ratios, surrounding parameters and the length of cultivation. 
The ratio of HPaSteC to PDAC cells was 1:4. As expected, the PDAC cells dominated the field 
when imaging. The HPaSteC often grow into pockets of grouped cells in between the PDAC cells. 
This is especially the case for the BxPC-3 cells in coculture with HPaSteC cells. One possibility 
is the BxPC-3 cells seems to grow on top of the HPaSteC cells, from Figure 4.6 A on day 21 the 
miRFP670 signal is barely visible but the growth kinetics from Figure 4.6 B shows that the signal 
still is high, even though they are not visible on the image. Another possibility is that they form 
clusters and even interact.  Previous studies show that fibroblast can be both tumor promoting and 
tumor suppressive. The depletion of αSMA+ fibroblast in mice led to more invasive tumors and 
decreased survival rate in both PanIN and pancreatic cancer stage. The heterogeneity of fibroblasts 




PSCs, which are the main source of cancer-associated fibroblasts in PDAC are crucial for the 
deposition of collagen-rich ECM in the tumor stroma and can affect the surrounding stromal cell. 
PSCs, when activated also express TGF-β which is crucial for upregulation of type-I collagen 
expression (113,114). The role of CAFs in PDAC cannot be understated and should be fully 
explored, both the different subtypes of CAFs and the activation of PSCs into CAFs. Targeting the 
stromal compartments or the signaling pathway crucial for  type-I collagen deposits can be the 
pathway to more effective treatments. The results from these experiments also show that a higher 
starting number of PSCs do not translate into an increased growth signal, since cultures from 12 x 
103 to 50 x 103 reach the same signal intensity. It would however be interesting to see how different 
starting number of PSCs influence the growth of PDAC cell lines. These experiments had a 1:4 
ratio between PSCs and PDAC cells, increasing the number of PSCs to an equal amount or even 
more could reveal how much PSCs affect the growth pattern of PDAC cells. 
 
5.4 Comparison between SISser and PanMa  
The growth pattern of PANC-1 cells alone and in coculture was compared using SISser and PanMa 
scaffolds. The main goal of using pancreas as biological scaffolds is to find out to what extend the 
matrix composition and biophysical properties influence tumor cell and PSC growth. Previous 
publication have shown these properties (94). After cultures were established on SISser, we used 
PANC-1 cells on PanMa which more closely mimics human pancreas composition, maintaining 
physical properties like stiffness and cell-ECM interactions. The results from Figure 4.8 show 
remarkable similarities between the two different scaffolds with PANC-1 cells. The same cannot 
be said for HPaSteC, which grew on SISser but barely at all on PanMa.  HPaSteC were only grown 
in coculture with PANC-1 on PanMa, growing HPaSteC on PanMa in monoculture would show if 
HPaSteC can proliferate similarly as on SISser, or if the ECM composition is not suitable for 
HPaSteC.  Even though the process of making SISser and PanMa scaffolds are similar, their 
composition is different. The ECM on PanMa is not as stiff as on SISser, and it has a higher storage 
capacity for water that can act as a reservoir for dissolved molecules. Hepatic stellate cells have 
been shown to require  a stiff ECM to enable differentiation, even in the presence of TGF-β (115). 
Probably, pancreatic stellate cells need a higher degree of scaffold stiffness as well wherefore, 
HPaSteC did grow on SISser and not on PanMa. The different scaffolds have unique mechanical 
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properties, depending on the organ of origin (94). As discussed earlier, CAFs have a profound 
effect on tumor proliferation and chemotherapeutic resistance. But changes in the physical 
properties of the microenvironment also affect the cells within. When the tumor becomes 
desmoplastic it often develops fiber patterns that are aligned, making the ECM stiffer (116). The 
rigidity of the tumor increases the stromal stiffness and tumor cell tension, with small increases in 
rigidity alters tissue architecture and increases growth by ERK-activation (117). Latent TGF-β 
present in the ECM can be activated by mechanical forces (118), the stiffness can as well  promote 
mesenchymal characteristics (119). It is also suggested that CAFs generate more force in response 
to ECM stiffening, working as a positive feedback-loop for more CAF development until a certain 
stiffness-threshold is reached (120). Interestingly, stromal fibroblast harvested in vivo from 
different tumor stages require a 3-dimentional environment to maintain their tumor-associated 
stromal characteristics within in vitro cultures (121). As PANC-1 grew nearly identical in 
monoculture and in coculture with HPaSteC, both on SISser and PanMa, indicate that they do not 
interact with each other in this model system. 
 
5.5 Dynamic culture  
The bioreactor which allowed for dynamic 3D culture was specifically designed for our lab. It has 
not been standardized yet and the microfluidic streams have been modelled but not controlled. A 
comparable system has been used before, culturing colorectal cancer cells on the mucosal layer of 
decellularized porcine intestine (SISmuc), in dynamic conditions. These results showed that 
dynamic cell culture conditions support tumor tissue generation and association with the tumor–
stroma (122). Our dynamic culture experiments were not successful. Several different variations 
in speed and static culture duration were tried, but none proved successful, and no cells were 
observed with histological analysis. This was done with PANC-1 cells grown on SISser, so the 
problem could be that they just do not attach well enough to the scaffold. The moving fluid may 
be responsible making the cells detach, resulting in an empty scaffold. Another reason may be 
poor gas exchange between the medium and the environment, inside the specialized incubator. We 
are convinced that optimizing the conditions within our bioreactor would make dynamic cultures 




5.6 Future perspectives  
These experiments focus on determining the optimal experimental set up, with focus on 
morphology and growth patterns. The insights need to be further expanded to use patient material.  
A more in-depth characterization by proteome profiling or immunohistochemistry of the PDAC-
PSCs interactions on both SISser and PanMa scaffolds would be interesting, since the activation 
of PSCs on an intracellular level is not fully characterized. Previous studies have shown that PDAC 
cells grown in the secretome of activated PSCs inhibit apoptosis and induced proliferation (123). 
Since our experiments did not show any significant difference between PANC-1 in monoculture 
and cocultures of PANC-1 and HPaSteC, recreating these experiments with factors that activate 
PSCs such as cytokines like TGF-β and platelet derived growth factor or by inducing oxidating 
stress can bring new insights into the importance of the stromal cells (124). 
Detailing the difference composition and biophysical characteristics in ECM of porcine small 
intestine and pancreas to human is important, since the ECM compositions needs to overlap for 
the model system to be relevant. Since patient material is rare and in limited quantity, proper 
characterization of the cell lines and ECM is essential to provide insight how the model will work 
with patient material, so none is wasted.  
 
Exploring the options of immune-present cocultures could give new insight into PDAC biology 
and help explain the unique properties of different immune cells. As discussed earlier; the immune 
cells in PDAC can both be tumor promoting or tumor suppressive, depending on the features of 
the present immune cells. The microenvironment of PDAC also includes a heterogenous 
population of fibroblasts. Including the heterogenous fibroblast population with immune cells 
could provide a more realistic microenvironment. This model system allows the culturing of cells 
both in static conditions and in dynamic conditions. With bioreactors, the ability to control the 
tissue-fluid pressure becomes possible. High intra-tumoral pressure is a defining feature of PDAC, 
which makes treatments less effective. Having the ability to control the pressure within a system 
is crucial for mimicking the microenvironment as closely to a real PDAC environment as possible. 
Shifting from static to dynamic conditions should be a priority, that in the end makes the model 




More work needs to be done to understand the interactions between treatments and cell cultures 
with our model system. Repeated experiments together with cell viability assays such as MTT, 
should be performed, as MTT assays have shown that PDAC cells show a dose-dependent 
reduction in cell viability after exposure to GEM (125). Small morphological differences were 
observed between the treated cells and control, indicating that cell the cells were affected by the 
GEM, even though the GFP-signal was stable.  
 
Chemotherapeutic agents, even with their low effectiveness are currently the best treatment option 
for non-resectable tumors. Once cocultures with immune cells have been established, 
immunotherapies targeting and activating T-cell or monoclonal antibodies or small molecular 
inhibitors targeting growth receptors and checkpoint inhibitors can be implemented. 
The main goal for the development of this 3D model using SISser and PanMa is to predict the 
effectiveness of treatments and tumor response more accurately. Hopefully, novel treatments can 
be applied effortlessly once the system is established. If the response to therapies is more 
accurately determined, this will then subsequently lead to a reduction in animal used in pre-clinical 
models.  
 
In the end, the 3D model system using SISser and PanMa scaffolds shows promise as a pre-clinical 
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